Inferra AIResearch Tools

Inferra AI / Company / VREX

Varex Imaging Corp

VREX · Health Care

Last earnings Aug 10, 2026

Key results

Revenuequarter

$203 million

Revenues of $203 million GAAP gross margin 33% Non-GAAP gross margin* 34% GAAP operating margin (40)% Non-GAAP operating margin* 8% GAAP net loss $(2.15) per diluted share Non-GAAP net earnings* $0.18 per diluted share Cash flow from operations was $8 million Sunny Sanyal, Chief Executive Officer, stated

SEC original ↗Varex Imaging Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

GAAP gross marginquarter

33%

Revenues of $203 million GAAP gross margin 33% Non-GAAP gross margin* 34% GAAP operating margin (40)% Non-GAAP operating margin* 8% GAAP net loss $(2.15) per diluted share Non-GAAP net earnings* $0.18 per diluted share Cash flow from operations was $8 million Sunny Sanyal, Chief Executive Officer, stated

SEC original ↗Varex Imaging Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Non-GAAP gross marginquarter

34%

Revenues of $203 million GAAP gross margin 33% Non-GAAP gross margin* 34% GAAP operating margin (40)% Non-GAAP operating margin* 8% GAAP net loss $(2.15) per diluted share Non-GAAP net earnings* $0.18 per diluted share Cash flow from operations was $8 million Sunny Sanyal, Chief Executive Officer, stated

SEC original ↗Varex Imaging Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Non-GAAP operating marginquarter

8%

Revenues of $203 million GAAP gross margin 33% Non-GAAP gross margin* 34% GAAP operating margin (40)% Non-GAAP operating margin* 8% GAAP net loss $(2.15) per diluted share Non-GAAP net earnings* $0.18 per diluted share Cash flow from operations was $8 million Sunny Sanyal, Chief Executive Officer, stated

SEC original ↗Varex Imaging Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Non-GAAP net incomequarter

$0.18

Revenues of $203 million GAAP gross margin 33% Non-GAAP gross margin* 34% GAAP operating margin (40)% Non-GAAP operating margin* 8% GAAP net loss $(2.15) per diluted share Non-GAAP net earnings* $0.18 per diluted share Cash flow from operations was $8 million Sunny Sanyal, Chief Executive Officer, stated

SEC original ↗Varex Imaging Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Varex s revenue of $203 million was down 3% year-over-year.

SEC original ↗Varex Imaging Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Medical segment revenue of $142 million was down 4% year-over-year.

SEC original ↗Varex Imaging Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Industrial segment revenue of $61 million was up 1% year-over-year.

SEC original ↗Varex Imaging Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Non-GAAP gross margin was 34% in the quarter compared to 32% in the third quarter of fiscal year 2024 and non-GAAP EPS increased to $0.18 in the quarter from $0.14 in the third quarter of fiscal year 2024.

SEC original ↗Varex Imaging Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Research and developmentquarter

$21.4 million

Research and development 21.4 22.0 66.9 65.1

SEC original ↗Varex Imaging Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

AI analysis

Q3 FY2025 · reported Aug 7, 2025

Based on: Earnings release + parent 8-K — transcript not held

Revenue · Q3 FY2025
$203M
EX-99 · Aug 7, 2025
GAAP gross margin · Q3 FY2025
33%
EX-99 · Aug 7, 2025
Diluted EPS · non-GAAP · Q3 FY2025
$0.18
EX-99 · Aug 7, 2025
Non-GAAP gross margin · Q3 FY2025
34%
EX-99 · Aug 7, 2025

Headline figures

MetricQ3 FY2025Prior qtrYear ago
Revenue$203 million——
GAAP gross margin33%——
Non-GAAP gross margin34%——
Non-GAAP operating margin8%——
Non-GAAP net income$0.18——
Research and development$21.4 million——

EX-99 · Aug 7, 2025

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

Margin

GAAP gross margin33%
Non-GAAP gross margin34%
Non-GAAP operating margin8%

Capital allocation

These may include such items as legal settlements, inventory write-downs for discontinued products, cost of facilities no longer in use, extinguishment of debt and hedge costs, environmental settlements, governmental settlements including tax settlements, and other items of similar nature.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Varex Imaging Corp Q3 FY2025 — Revenues of $203 million GAAP gross margin 33% Non-GAAP gross margin* 34% GAAP operating margin (40)% Non-GAAP operating margin* 8% GAAP net loss $(2.15) per diluted share Non-GAAP net earnings* $0.18…

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

These may include such items as legal settlements, inventory write-downs for discontinued products, cost of facilities no longer in use, extinguishment of debt and hedge costs, environmental settlements, governmental settlements including tax settlements, and other items of similar nature.

SEC original ↗Varex Imaging Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Risks & headwinds

Statements concerning unaudited financial results revenue and earnings guidance tariffs and trade wars and their impact on our customers industry or business outlook, including for our business in China product demand environment expected future financial results or performance and any statements using the terms assume, believe, encouraged, expect, can, will, could, may, and potential or similar statements are forward-looking statements that involve risks and uncertainties that could cause Varex s actual results and the outcome and timing of certain events to differ materially from those anticipated.

SEC original ↗Varex Imaging Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

While forward-looking statements are based on assumptions and analyses made by management of Varex that it believes to be reasonable under the circumstances, whether actual results and developments will meet such expectations depends on a number of risks and uncertainties which could cause actual results, performance, and financial condition to differ materially from such expectations.

SEC original ↗Varex Imaging Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Non-ordinary course litigation W e may incur charges that result from non-ordinary course litigation matters such as certain intellectual property disputes and joint venture litigation.

SEC original ↗Varex Imaging Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Litigation matters that are part of the ordinary course of the Company s business, such as product liability claims, employment related matters and commercial contract disputes, are not excluded.

SEC original ↗Varex Imaging Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

30 documents

Earnings releases

11 documents

Presentations

0 documents

No presentations for Varex Imaging Corp are held in this edition of the library.

Transcripts

0 documents

No transcripts for Varex Imaging Corp are held in this edition of the library.

Mentioned by

1 company

Other tracked companies whose held documents mention Varex Imaging Corp by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.